These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Elimination kinetic of high polar metabolites pool of quinidine from human serum. Camsonne R; Moulin MA; Charbonneau P; Bazin C Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):74-5. PubMed ID: 3988396 [TBL] [Abstract][Full Text] [Related]
3. Accumulation of 3-hydroxyquinidine following chronic quinidine therapy. Ackerman BH; Olsen KM; Pappas AA DICP; 1991; 25(7-8):867-9. PubMed ID: 1949948 [No Abstract] [Full Text] [Related]
4. Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state. Wooding-Scott RA; Visco J; Slaughter RL Am Heart J; 1987 Feb; 113(2 Pt 1):302-6. PubMed ID: 3812182 [TBL] [Abstract][Full Text] [Related]
5. Disposition of 3-hydroxyquinidine in patients receiving initial intravenous quinidine gluconate for electrophysiology testing of ventricular tachycardia. Ackerman BH; Olsen KM; Kennedy EE; Taylor EH; Chen BH; Jordan D; Ackerman DJ DICP; 1989 May; 23(5):375-8. PubMed ID: 2728524 [TBL] [Abstract][Full Text] [Related]
6. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. Edwards DJ; Lavoie R; Beckman H; Blevins R; Rubenfire M Clin Pharmacol Ther; 1987 Jan; 41(1):68-73. PubMed ID: 3802708 [TBL] [Abstract][Full Text] [Related]
7. Prolonged quinidine half-life with associated toxicity in a patient with hepatic failure. Stanek EJ; Simko RJ; DeNofrio D; Pavri BB Pharmacotherapy; 1997; 17(3):622-5. PubMed ID: 9165569 [TBL] [Abstract][Full Text] [Related]
8. Evidence supporting 3(S)-3-hydroxyquinidine-associated cardiotoxicity. Bowers LD; Nelson KM; Connor R; Lais CJ; Krauss E Ther Drug Monit; 1985; 7(3):308-12. PubMed ID: 4049469 [No Abstract] [Full Text] [Related]
9. [Chronic renal insufficiency. Elevated levels of the active metabolite (3-hydroxyquinidine) of quinidine]. Camsonne R; Moulin MA; Ryckelynck JP; Mignot P; Albessard F; Perault M; Bigot MC; Richard O Nouv Presse Med; 1982 Oct; 11(41):3062-3. PubMed ID: 7145692 [No Abstract] [Full Text] [Related]
10. [Quinidine and enzyme induction. Erroneous interpretation of the plasma levels of 3-hydroxyquinidine and O-demethylquinidine]. Leroyer R; Jarreau C; Pays M Therapie; 1984; 39(1):57-9. PubMed ID: 6463946 [No Abstract] [Full Text] [Related]
11. [Clinical pharmacology of anti-arrhythmia agents. I. Quinidine, procainamide and disopyramide]. Witkowska M Kardiol Pol; 1981; 24(7):505-17. PubMed ID: 7024612 [No Abstract] [Full Text] [Related]
12. [Estimation of residual rate and apparent half-life time of drugs using the method of acute mortality of animals]. He MS; Zhan LF; Guo JY; Zhang YZ Zhongguo Yao Li Xue Bao; 1985 Sep; 6(3):213-6. PubMed ID: 2943131 [No Abstract] [Full Text] [Related]
13. Greater quinidine-induced QTc interval prolongation in women. Benton RE; Sale M; Flockhart DA; Woosley RL Clin Pharmacol Ther; 2000 Apr; 67(4):413-8. PubMed ID: 10801251 [TBL] [Abstract][Full Text] [Related]
15. Phenytoin-induced changes in quinidine and 3-hydroxyquinidine pharmacokinetics in conscious dogs. Jaillon P; Kates RE J Pharmacol Exp Ther; 1980 Apr; 213(1):33-7. PubMed ID: 7359368 [No Abstract] [Full Text] [Related]
16. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)]. Knapp W; Lechleitner P Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960 [TBL] [Abstract][Full Text] [Related]
17. Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. Trenk D; Möhrke W; Warth L; Jähnchen E Arzneimittelforschung; 1993 Aug; 43(8):836-41. PubMed ID: 8216438 [TBL] [Abstract][Full Text] [Related]